Recent Updates
Recently added Catalysts

Huntington's Disease: two biotech companies racing to a treatment

Neurology & PsychiatryConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$2.8Buniverse median $1.20B
Allocated capital$2.4B$5.5B competing
Phase 3 or filed00 mid, 2 early
Pure plays0this indication only
Capital rank82/299crowding rank 81

Huntington's Disease is a two-horse race: uniQure (QURE, $3.1B) against Sarepta Therapeutics (SRPT, $2.4B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $2.4B of allocated capital sits on the pair.

QURE carries 56% of the $5.5B competing here, so the pair is far from evenly matched.

$2.4B of allocated capital sits in Huntington's Disease, ranking it 82nd of 299 indications by the money committed to it.

Companies developing drugs for Huntington's Disease 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
QUREuniQureintra-striatal rAAV5-miHTTPhase 12$3.1BNo2 30 Sep 2026
SRPTSarepta TherapeuticsSRP-1005Phase 11$2.4BNo3No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile. QURE holds 56% of the $5.5B competing in this indication.

Why Huntington's Disease is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Huntington's Disease has 2 competitors and a median of $2.8B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Parkinson's Disease5 companies · $2.5B · median $1.3BConcentrated betNarcolepsy Type 11 company · $2.6B · median $7.9BUncontestedChorea1 company · $2.7B · median $16.1BUncontestedObsessive Compulsive Disorder1 company · $2.7B · median $16.1BUncontestedMyotonic Dystrophy Type 13 companies · $2.0B · median $250MOrphan cornerExcessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontestedSmoking Cessation1 company · $2.7B · median $10.9BUncontestedMultifocal Motor Neuropathy1 company · $2.0B · median $5.9BUncontested

Huntington's Disease pipeline questions

Which biotech companies are developing drugs for Huntington's Disease?

uniQure (QURE, intra-striatal rAAV5-miHTT, Phase 1); Sarepta Therapeutics (SRPT, SRP-1005, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Huntington's Disease.

How advanced is the Huntington's Disease pipeline?

Of the 2 clinical-stage programmes in Huntington's Disease, 0 are in Phase 3 or filed, 0 are in mid-stage development and 2 are in early-stage development.

Which company leads the Huntington's Disease field?

QURE is the largest developer in Huntington's Disease, holding 56% of the $5.5B of market capitalisation competing in the indication. The median competitor is worth $2.8B.

When is the next Huntington's Disease catalyst?

The next dated catalyst in Huntington's Disease is QURE on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map